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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• In previous work, we showed a long-term
and concentration-dependent beneficial
effect of the non-nucleoside reverse
transcriptase inhibitor efavirenz (EFV) on
high-density lipoproteins (HDL) in human
immunodeficiency virus (HIV)-infected
patients.
• Furthermore, it has been suggested that
instead of the current practice of only
measuring HDL-chelesterol values, the
evaluation of HDL function, namely its
antioxidant properties, might be an
improved tool for identifying subjects at
increased risk for cardiovascular events.
• Paraoxonase-1 (PON-1) is an enzyme
associated with HDL that is responsible for
HDL antioxidant function.
WHAT THIS STUDY ADDS
• In the present work, we studied the effect of
EFV on the activity of PON-1 and showed,
for the first time, that EFV-based
antiretroviral therapy is associated with a
better antioxidant function, i.e. with a higher
PON-1 activity.
AIMS
A long-term and concentration-dependent beneficial effect of
efavirenz (EFV) on cholesterol associated with high-density lipoprotein
(HDL-c) in human immunodeficiency virus (HIV)-infected patients has
been documented. Furthermore, it has been suggested that, instead of
the current practice of only measuring HDL-c values, the evaluation of
HDL quality might be an improved tool for identifying subjects at
increased risk of cardiovascular events. Paraoxonase-1 (PON-1) is an
enzyme associated with HDL that is involved in the onset of
cardiovascular disease and responsible for HDL antioxidant function.
The aim of the present study was to investigate the effect of EFV on
the circulating activity of PON-1 in HIV-infected patients.
METHODS
The patients included were adults with a documented HIV-1 infection,
nontreated or treated with antiretroviral regimens including EFV
600 mg once daily as first therapeutic regimen for at least 3 months.
The influence of treatment with EFV, HDL-c and CD4 cell count on
PON-1 activity was analysed.
RESULTS
HIV-infected White patients treated with EFV had higher PON-1 activity
[77.35 U l-1 (65.66, 89.04)] (P < 0.05) and higher PON-1 activity : HDL-c
ratio [1.88 (1.49, 2.28)] (P < 0.01) than untreated patients. PON-1 activity
was higher in Black patients (P < 0.001) and in patients with a CD4 cell
count >500 cells ml-1 (P = 0.0120).
CONCLUSIONS
EFV-based antiretroviral regimens are associated with HDL particles
with a better antioxidant function, i.e. with a higher PON-1 activity. The
PON-1 activity of Black patients is higher than that found in Whites
regardless of treatment. Ethnicity should be taken into consideration
when studying drug effects on PON-1 activity.
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Introduction
The combination of three drugs [two nucleoside
analogues (NRTI) and a protease inhibitor (PI) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI)] that can
inhibit the replication of the human immunodeficiency
virus (HIV) leads to a dramatically improved outcome for
this chronic infection [1]. However, while the benefits of
this highly active antiretroviral therapy (HAART) have revo-
lutionized the life expectancy of HIV-infected patients,
treatment-associated dyslipidaemia has frequently been
observed [2]. This includes an increase in the atherogenic
nonhigh-density-lipoprotein cholesterol (non-HDL-c) [3].
Whereas many of the PI-based regimens are often associ-
ated with increased concentrations of triglycerides (TG),
total cholesterol and low-density lipoprotein cholesterol
(LDL-c), NNRTI-based regimens differ importantly, being
associated with increases in HDL [4–6].
It has also been shown that infection, in itself, causes a
significant drop in HDL [7].For instance,HDL-c decreases in
HIV-infected individuals [7, 8] and the viral replication is
related to cholesterol membrane metabolism [9].Also,Nef,
the accessory protein of HIV-1, impairs cholesterol efflux
from the macrophages [10].
The role of HDL-c as a protective factor against cardio-
vascular disease is well documented [11]. On the other
hand, levels of HDL-c have been significantly associated
with a better HIV infection course [12]. Furthermore, it has
been suggested that, instead of the current practice of only
measuring HDL-c values, the evaluation of HDL quality
might be an improved tool for identifying subjects at
increased risk of cardiovascular events [13].
Regarding quality, HDL are heterogeneous particles
containing variable levels of antioxidants that are, in part,
related to enzymes associated with HDL [13, 14]. This
results in a different functionality/quality and protective
effect of HDL.
Paraoxonase-1 (PON-1) is an antioxidant enzyme asso-
ciated with HDL, mechanistically linked to systemic oxida-
tive stress and prospectively to cardiovascular risk, thus
indicating a potential mechanism for its atheroprotective
function [15]. Navab et al. [14] showed that patients with
coronary atherosclerosis had lower PON-1 activity than
healthy controls, despite having the same HDL-c level.This
suggests that HDL antioxidant properties are more useful
in distinguishing the cardiovascular risk of patients and
healthy controls than the amount of HDL-c [13].
PON-1 is highly effective in preventing lipid peroxida-
tion of LDL [16]. However, PON-1 may be partially inacti-
vated in the presence of oxidative stress. Several results
corroborate that substantial oxidative stress occurs
[17–19] and PON-1 activity decreases [20] during HIV infec-
tion. In addition,Masiá and co-authors [19] compared total
peroxide concentration in a cohort of patients and
reported an association between a NNRTI-based HAART
and low peroxide concentrations.
Efavirenz (EFV) is a NNRTI that has been associatedwith
a long-term and concentration-dependent beneficial
effect on HDL-c [21].However its effects on HDL quality are
unknown.The present work was aimed to study the effect
of EFV-based antiretroviral regimens on HDL quality, par-
ticularly on PON-1 activity.
Methods
Patients with documented HIV infection who had received
continuous treatment with EFV 600 mg once daily as first
therapeutic regimen for at least 3 months were invited to
participate. A second group of patients with documented
HIV infection but without indication to start antiretroviral
treatment was considered as control. Exclusion criteria
were aspartate aminotransferase or alanine aminotrans-
ferase more then five times the upper limit of normal,
drugs for dyslipidaemia and other viral co-infections
besides HIV.The protocol received prior approval from the
Ethics Committee of Centro Hospitalar de Lisboa, Central
(Desterro).All patients gave their written informed consent
and agreed on adherence to treatment. Before sample
collection patients were asked about compliance issues
and only those patients who confirmed adherence were
included.
PON-1 activity was obtained from 46 patients assessed
by spectrophotometry, through the quantification of p-
nitrophenol formation as previously described by Batuca
et al. [22]. The reaction medium was a glycine buffer
(0.05 mol l-1, pH 10.5) with 1 mmol l-1 CaCl2. The tempera-
ture of the reaction was 37 °C. PON-1 activity was calcu-
lated with a molar extinction coefficient of 18.290 M cm-1
and expressed as U l-1, which is defined as 1 mmol of
p-nitrophenol generated per minute per litre, under
assay conditions.As paraoxon is very unstable, the reagent
was prepared immediately before use. Regarding para-
oxon toxicity, stock solutions were handled in an air-
extraction fumehood and the operator took appropriate
safety precautions, such as wearing a mask and gloves
to protect against accidental contact or inhalation of
the toxic fumes.
Drug plasma concentrations were obtained from 25
patients by high-performance liquid chromatographywith
UV detection method described elsewhere [23].
EFV is generally taken once daily at bedtime to improve
its tolerability and minimize its psychiatric and central
nervous system adverse effects, which makes it more diffi-
cult to determine through concentrations in an outpatient
setting. Blood samples were thus taken during the
morning, 8–16 h post dosing. It has been previously dem-
onstrated that, given the long half-life of EFV, mid-interval
sampling at 8–16 h post dose influences the total variance
in EFV concentrations only slightly [23].
The samples for PON-1 activity and EFV concentration
determination were time matched.
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Plasma samples for lipid profile determination were
analysed in the local clinical pathology laboratory by stan-
dard enzymatic assays.
Results were shown asmean (95% confidence interval).
Normally distributed variables were analysed using the
unpaired Student’s t-test while non-normally distributed
variables were compared using the Mann–Whitney U-test.
Correlations between Gaussian variables were performed
using the Pearson correlation test, while nonparametric
correlation was performedwith Spearman’s test. Statistical
significance was assumed at P < 0.05. GraphPad Prism
version 4 (GraphPad Software Inc., San Diego,CA,USA) was
used to perform data and statistical analysis. Determina-
tion of independent predictors was done using SPSS (SPSS
Inc., Chicago, IL, USA).
Results
The study was conducted in 46 HIV-infected patients
(Table 1): (i) 21 untreated patients (control group), and (ii)
25 patients who had received continuous treatment with
EFV 600 mg once daily as first therapeutic regimen for at
least 3 months (study group).
PON-1 activity was higher in treated patients [n = 25;
85.46 U l-1 (75.49, 95.44)] than in the nontreated group
[n = 21; 65.58 U l-1 (55.77, 75.39)] (P = 0.0067; unpaired
Student’s t-test).
As the demographic characteristics of the patients may
influence PON-1 activity, a multivariate analysis was con-
ducted to ensure that this was an independent associa-
tion.The possible independent effect of age, sex, ethnicity
and treatment with EFV on PON-1 activity was assessed in
a regression model that revealed ethnicity and treat-
ment with EFV as being independently associated with
PON-1 activity (t = 2.440, P = 0.019 and t = 4.879, P < 0.001,
respectively).
Race-related differences were found in PON-1 activity
(P < 0.01; one-way ANOVA plus Bonferroni’s multiple com-
parison test; Figure 1). Within the Black patients, treated
and nontreated groups were different in sample size and
demographic characteristics.No differences in sample size,
demographic characteristics (age, sex and body mass
index), CD4 cell count, lipid and liver function profile were
found within Whites (n = 36) (Table 2).
The PON-1 activity : HDL-c ratio and PON-1 activity
and were higher in White individuals on EFV (P = 0.0082;
unpaired Student’s t-test) (Table 2).
In patients with CD4 >500 cells ml-1, PON-1 activity was
positively related with CD4 cell count (Pearson r = 0.6105;
P = 0.0120, n = 16). The CD4 cell count was higher with
increasing HDL values (Pearson r = 0.3786; P = 0.0249, n =
35) and TG values (Pearson r = 0.3728; P = 0.0299, n = 34).
Table 1
Diagram of the groups and subgroups of the study population
Total HIV-infected individuals
(n = 46)
Treatment Naive on efavirenz
(n = 21) (n = 25)
Ethnicity Black White Black White
(n = 3) (n = 18) (n = 7) (n = 18)
Antiretroviral backbone Lamivudine + zidovudine (n = 7)
Tenofovir + emtricitabine (n = 8)
other drug association (n = 3)
n, number of patients.
P
O
N
-1
 (
U
/L
)
Caucasian Black
125
100
75
50
25
***
**
***
Figure 1
Paraoxonase-1 (PON-1) activity in human immunodeficiency virus (HIV)-
infected individuals. PON-1 activity was lower in untreated [58.80 U l-1
(51.36, 66.23); n = 18] than in treated [77.35 U l-1 (65.66, 89.04); n = 18]
White patients and both were lower than Black patients despite treat-
ment (*P < 0.05, **P < 0.01 and ***P < 0.001, one-way ANOVA plus Bonfer-
roni’s multiple comparison test). No treatment (); EFV ()
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These relations were observed from an analysis conducted
on the entire cohort. However, as the differences in CD4
count between these patients could create a high likeli-
hood of bias, multivariate analysis was further performed
in the group of patients on EFV.The possible independent
effects of age, sex, CD4 count and treatment duration on
PON-1 activity were assessed in a regression model that
revealed that none of the variables was independently
associated with PON-1 activity.
Mean EFV plasma concentration was 2.47 mg l-1 (1.80,
3.15) and no association was found between drug plasma
level and PON-1 activity.
The NNRTI backbone of HAART did not influence
PON-1 activity [seven patients lamivudine + zidovudine
78.94 U l-1 (54.01, 103.9) and eight patients on tenofovir +
emtricitabine 78.75 U l-1 (58.92, 98.58)].
Discussion and conclusions
In the present work,a positive effect of EFV on PON-1 activ-
ity in HIV-infected patients has been described for the
first time. Also, we have shown that ethnicity can not
be excluded in studies of PON-1 activity.
PON-1 activity in HIV-infected patients on EFV was
higher than in HIV-infected patients without treatment.
Recently, a relation between this enzyme and its capacity
to promote systemic antioxidant effects in humans with
systemic oxidative stress and cardiovascular risk has been
suggested [15, 24]. It has also been shown that concen-
trations and activity of PON-1 are altered in chronic
diseases [20, 25], probably as a response to the enhanced
oxidative stress observed in the earlier stages of these
diseases. Furthermore, changes in oxidative stress
markers, antioxidant capacity, lipid profiles in HIV-infected
patients and cardiovascular risk have been recently
described [8, 19].
The mechanism behind the effect of EFV on PON-1
activity remains speculative. In untreated patients, the
lower PON-1 activity can be the result of increased inacti-
vation of the enzyme due to increased generation of
reactive oxygen species [19]. EFV could also be acting as
a scavenger of reactive oxygen species, enabling higher
PON-1 activity. In addition, it has been shown that alter-
ations in HDL structure and composition can affect PON-1
activity and function [26]. The effect of HIV infection on
HDL metabolism is well documented [8], and we have pre-
viously shown that EFV is associated with higher values of
HDL-c [21]. Thus the alterations of HDL-c caused by EFV
could be stabilizing the link of the enzyme to HDL, hence
allowing higher enzymatic activity. In short, we can specu-
late that EFV can balance the inactivation of the enzyme
by reducing oxidative stress status and/or inducing new
HDL structural alterations, counteracting the effects of the
infection. Another hypothesis is that the drug is acting
as an inducer of the enzyme.Further studies are warranted
to establish the underlying mechanism.
As the study design was not prospective, the percent-
age increase in both HDL-c concentrations and PON-1
activity, in relation to basal values (before start of treat-
ment),can not be evaluated.However, in the treated group,
in addition to the higher PON-1 activity, a higher PON-1
Table 2
Comparison between demographic and biochemical variables between White HIV-infected patients without treatment and HIV-infected patients treated
with efavirenz (EFV)
Parameter
HIV–infected patients
P-valueUntreated EFV
n 18 18
Male 11 15
Age (years) 38 (32, 43) 44 (37, 51) NS
Body mass index (kg m-2) 25 (22, 28) 23 (22, 25) NS
GGT (U l-1) 32 (13, 50) 49 (20, 77) NS
AP (U l-1) 65 (52, 78) 87 (69, 104) NS
AST (U l-1) 24 (15, 33) 20 (17, 23) NS
ALT (U l-1) 38 (20, 55) 29 (20, 39) NS
CD4 cell count (cells mm-3) 492 (397, 588) 594 (445, 742) NS
TC (mg dl-1) 179 (159, 200) 187 (173, 200) NS
LDL-c (mg dl-1) 118 (98, 138) 115 (99, 131) NS
HDL-c (mg dl-1) 48 (42, 54) 46 (39, 52) NS
TG (mg dl-1) 89 (68, 109) 126 (90, 162) NS
TC : HDL-c ratio 3.86 (3.30, 4.14) 4.35 (3.71, 4.98) NS
PON-1 activity (U l-1) 58.80 (51.36, 66.23) 77.35 (65.66, 89.04) <0.05
PON-1 activity : HDL-c ratio 1.30 (1.11, 1.49) 1.88 (1.49, 2.28) <0.01
Data are expressed has mean (95% CI). NS, nonsignificant (P > 0.05); n, number of patients; GGT, g-glutamyltranspeptidase; reference range (RR) < 36 U l-1; AP, alkaline phosphatase;
RR 35–104 U l-1; AST, aspartate aminotransferase; RR < 31 U l-1; ALT, alanine aminotransferase; RR < 31 U l-1. To convert total cholesterol (TC) high-density (HDL-c) and low-density
(LDL-c) lipoprotein cholesterol to mmol l-1 multiply by 0.0259. For triglycerides (TG), the conversion value is 0.0113. RR, TC < 200 mg dl-1; TG < 150 mg dl-1, HDL-c > 40 mg dl-1,
LDL-c < 150 mg dl-1.
S. A. Pereira et al.
894 / 68:6 / Br J Clin Pharmacol
activity : HDL-c ratiowas also found.This observation raises
an interesting consideration.As PON-1 has been described
as preferentially associated to HDL and EFV increases
HDL, changes in the PON-1 activity : HDL-c ratio were not
expected. This higher ratio observed suggests that, for
patients on EFV, at least part of the higher PON-1 activity
found appears to be independent of HDL-c variation.
It has been suggested that within the patients with the
same HDL-c value, lower PON-1 activity is predictive of
coronary heart disease [14]. Moreover, other authors have
also suggested that the ability of HDL to inhibit oxidation
of lipoproteins is more important than the HDL-c concen-
tration [13]. Thus, the present study suggests that EFV
elicits HDL with more antioxidant capacity.
Another conclusion of our work is that ethnicity should
be taken into consideration when studying PON-1 activity.
It has been known that the distribution of PON-1 polymor-
phisms differs with ethnicity [27–29].The focal approach of
the association of different end-points of cardiovascular
problems and PON-1 arrived from genotype studies [30].
However, some authors have highlighted the role of PON-1
activity determinations [30,31], safeguarding the necessity
to perform functional studies. Among the different ethnic
populations, there are also marked differences in PON-1
activity [32], although in most studies no references have
been made to ethnicity.
In the present work we have shown that PON-1 activity
in the entire cohort was lower in untreated patients and
in those with lower CD4 cell count, indicating that lower
PON-1 activity is associated with more severe infection. A
relation between CD4 cell counts and PON-1 activity was
previously described [20]. However, this work was per-
formed in HIV-infected patients under different antire-
troviral regimens and with >60% being co-infected with
hepatitis C virus (HCV). The authors described a negative
influence of HCV co-infection on PON-1 activity, but the
hepatic function of these patients was not categorized.
In the present work, viral hepatitis co-infection was an
exclusion factor, given that PON-1 is mainly synthesized by
the liver and PON-1 measurement has been proposed as
a marker of hepatic function [25].
It has been suggested that a strong association
between viral replication and both HDL [9, 10, 12] and host
antioxidant defence [33–35] exists. The positive relation-
ship between CD4 cell count and PON-1 activity suggests
that higher PON-1 activity is associated with a better
course of HIV infection and antiviral properties.
No correlations were found between plasma concen-
trations of EFV and PON-1 activity. However, study of this
relation requires the percentage of variation of PON-1
activity instead of absolute values. The association of
PON-1 activity with EFV concentrations is important to dis-
tinguish if the effect relies on the response to treatment
or on EFV per se. Nevertheless, excluding NNRTI [21, 36],
the majority of antiretroviral drugs have been described
as not affecting HDL-c [2,7].
Regarding methodological aspects, there have been
some issues regarding the measurement of PON-1 activity
[37]. There are no standardized methods for measuring
PON1 esterase activity. The differences in procedure imply
that values obtained from different laboratories vary con-
siderably, which complicates interlaboratory comparisons.
However, the method used here is the most widely used
[37].
In conclusion, EFV is associated with increased PON-1
activity, which is higher in Black patients and is associated
with a better disease course. Further studies are required
to clarify the mechanism by which EFV-based HAART is
associated with HDL particles with a better antioxidant
function, namely, with higher PON-1 activity.
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